Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 4, 2012
Previous Article Next Article

The MEP pathway and the development of inhibitors as potential anti-infective agents

Author affiliations

Abstract

The non-mevalonate (or MEP) pathway represents an essential biosynthetic route used by plants, algae, and eubacteria to generate isoprenoid precursors. The MEP pathway has also been genetically validated in pathogenic organisms such as P. falciparum and M. tuberculosis. As this pathway is absent in mammalian systems, the enzymes of the MEP pathway represent attractive targets for the development of novel herbicides and antimicrobial chemotherapeutics. This review examines the enzymes in the MEP pathway from a detailed medicinal chemistry and structural biology perspective. The binding modes of substrates and inhibitors are discussed, identifying key interactions that maybe exploitable in small molecule inhibitor design.

Graphical abstract: The MEP pathway and the development of inhibitors as potential anti-infective agents

Back to tab navigation

Supplementary files

Article information


Submitted
05 Dec 2011
Accepted
20 Jan 2012
First published
23 Jan 2012

Med. Chem. Commun., 2012,3, 418-433
Article type
Review Article

The MEP pathway and the development of inhibitors as potential anti-infective agents

I. Hale, P. M. O'Neill, N. G. Berry, A. Odom and R. Sharma, Med. Chem. Commun., 2012, 3, 418
DOI: 10.1039/C2MD00298A

Search articles by author

Spotlight

Advertisements